Overview
Cutis marmorata telangiectatica congenita (CMTC), also known as congenital generalized phlebectasia or Van Lohuizen syndrome, is a rare congenital vascular disorder characterized by a persistent, pronounced marbled (reticular) pattern of the skin caused by dilated surface blood vessels. Unlike the common and benign cutis marmorata (a temporary mottling of the skin seen in many newborns in response to cold), CMTC is present at birth and persists, often with a more striking, fixed, dark blue or purple reticular pattern. The condition primarily affects the skin but can involve multiple body systems. The hallmark feature is a localized or generalized reticulated (net-like) vascular pattern on the skin, which may be accompanied by skin atrophy, ulceration, and telangiectasias (small dilated blood vessels). The affected skin areas may appear thinner than normal. CMTC can be associated with asymmetry of the limbs (one limb being larger or smaller than the other), body asymmetry, and occasionally with other congenital anomalies including glaucoma, other eye abnormalities, syndactyly, and other vascular malformations. In some cases, it may overlap with or be part of broader vascular malformation syndromes such as macrocephaly-capillary malformation syndrome (M-CM syndrome). In many patients, the skin findings tend to improve gradually during the first few years of life, though they may not resolve completely. There is no specific cure for CMTC. Treatment is primarily supportive and symptomatic, focusing on monitoring and managing associated complications. Regular ophthalmologic examinations are recommended to screen for glaucoma, and orthopedic follow-up may be needed if limb asymmetry is present. Dermatologic monitoring is important for skin ulceration. Laser therapy has been used in some cases to address persistent telangiectasias. The overall prognosis is generally favorable, particularly in isolated cases without significant associated anomalies.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Cutis marmorata telangiectatica congenita.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Cutis marmorata telangiectatica congenita at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Cutis marmorata telangiectatica congenita.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cutis marmorata telangiectatica congenita.
Community
No community posts yet. Be the first to share your experience with Cutis marmorata telangiectatica congenita.
Start the conversation →Latest news about Cutis marmorata telangiectatica congenita
No recent news articles for Cutis marmorata telangiectatica congenita.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cutis marmorata telangiectatica congenita
What is Cutis marmorata telangiectatica congenita?
Cutis marmorata telangiectatica congenita (CMTC), also known as congenital generalized phlebectasia or Van Lohuizen syndrome, is a rare congenital vascular disorder characterized by a persistent, pronounced marbled (reticular) pattern of the skin caused by dilated surface blood vessels. Unlike the common and benign cutis marmorata (a temporary mottling of the skin seen in many newborns in response to cold), CMTC is present at birth and persists, often with a more striking, fixed, dark blue or purple reticular pattern. The condition primarily affects the skin but can involve multiple body syste
How is Cutis marmorata telangiectatica congenita inherited?
Cutis marmorata telangiectatica congenita follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Cutis marmorata telangiectatica congenita typically begin?
Typical onset of Cutis marmorata telangiectatica congenita is neonatal. Age of onset can vary across affected individuals.